American Heart Journal
Volume 145, Issue 5 , Pages 806-812, May 2003

Use of complementary and alternative medical therapies in patients with cardiovascular disease

  • Malissa J Wood, MD, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Mass, USA
    • Corresponding Author InformationReprint requests: Malissa J. Wood, MD, FACC, Massachusetts General Hospital VBK 508, 55 Fruit St, Boston, MA 02114, USA.
  • ,
  • Robert L Stewart, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
  • ,
  • Heather Merry, MSc

      Affiliations

    • Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
  • ,
  • David E Johnstone, MD, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
  • ,
  • Jafna L Cox, MD, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    • Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada

Abstract 

Background

Complementary and alternative medical (CAM) therapies are becoming increasingly popular, yet little information is available about the prevalence and patterns of CAM therapy use by patients with cardiovascular disease (CVD).

Methods

Interviewers administered telephone questionnaires to 107 patients randomly selected from a stratified cohort of 2487 eligible patients participating in a registry of patients with CVD.

Results

The current use of CAM therapies was reported by 64% of the patients surveyed. Nutritional supplements (40%) and megadose vitamins (35%) were the most frequently used preparations. Most CAM therapy users (65%) cited their underlying cardiac condition as the reason for taking such therapy. The most common sources of information about CAM were a friend or relative (43%) or the respondent’s usual physician. However, although 80% of respondents claimed that they had discussed their use of CAM therapies with their physician, 58% of respondents taking a potentially toxic cardiovascular medication (digoxin, warfarin, sotalol, or amiodarone) were simultaneously taking an oral supplement.

Conclusion

The use of CAM therapies was high in the cohort of patients surveyed. Physicians caring for patients with CVD need to inquire about CAM therapy use. Further scientific study should be performed to evaluate the potential benefits and risks of CAM therapies in this patient population.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The ICONS study is supported through a nondirected educational grant from Merck Frosst Canada and through in-kind support from the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada, and the Nova Scotia Department of Health.Dr Cox receives salary support from a Canadian Institutes of Health Research/Regional Partnership Program Investigator Award and a Clinical Research Scholarship from the Faculty of Medicine, Dalhousie University.

PII: S0002-8703(03)00084-X

doi:10.1016/S0002-8703(03)00084-X

American Heart Journal
Volume 145, Issue 5 , Pages 806-812, May 2003